Kura forms Caspian and retains 49.2% stake
Kura formed Caspian Therapeutics, contributed next-generation menin inhibitor assets and retained approximately 49.2% after a $50.0 million Series A financing.
Key Highlights:Original SEC Filing: Kura Oncology, Inc. [ KURA ] - 8-K - Sep. 09, 2026This is an AI-powered summary. It may contain inaccur…